The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?

Taking stock of the drug industry, from the lab to the medicine chest

August 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends? Selling copies of weight loss drugs such as Wegovy and Ozempic is only allowed during shortages. Can Hims & Hers find ways to avoid FDA action? By Katie Palmer and Nicholas Florko NIH launches $270 million anti-overdose research program for, and led by, Native Americans The National Collective Research Effort to Enhance Wellness (N-CREW) is the largest effort to target drug overdoses in native communities. By Lev Facher Genentech is shedding even more employees Today's biotech news includes more layoffs and downsizing in the biotech world, Hims GLP-1 strategy backlash, and Zepbound's price cut. By Meghana Keshavan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser